Wechalekar, K;
Wechalekar, AD;
(2021)
Wild-type transthyretin cardiac amyloidosis: When is a rare disease no longer a rare disease?
Journal of Nuclear Cardiology
, 28
pp. 2857-2859.
10.1007/s12350-020-02275-1.
Preview |
Text
Wechalekar_Wild-type transthyretin cardiac amyloidosis- When is a rare disease no longer a rare disease_AAM.pdf - Accepted Version Download (81kB) | Preview |
Abstract
In this issue of JNC, Cuscaden and colleagues report the prevalence of cardiac uptake (a hallmark of cardiac amyloidosis) in patients undergoing routine {99m}^Tc-HMDP (hydroxymethylene diphosphonate) and {99m}^Tc-MDP (methylene diphosphonate) scintigraphy, suggesting a high prevalence of the disease increasing with age.1
| Type: | Article |
|---|---|
| Title: | Wild-type transthyretin cardiac amyloidosis: When is a rare disease no longer a rare disease? |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1007/s12350-020-02275-1 |
| Publisher version: | https://doi.org/10.1007/s12350-020-02275-1 |
| Language: | English |
| Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher's terms and conditions. |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine > Inflammation |
| URI: | https://discovery-pp.ucl.ac.uk/id/eprint/10114982 |
Archive Staff Only
 |
View Item |
